The abstract is read at the publisher; the summary is JClub's.
CAS-X multi-tissue integration at Type 2 Diabetes risk loci prioritized 28 candidate effector genes across five tissues, versus 12 from pancreas-only, a 133.3% increase in coverage.
- Why it matters: Pancreas-focused prioritization can miss regulatory effects in other metabolic tissues relevant to T2D. CAS-X addresses this by integrating evidence across multiple tissue contexts.
- What they did: CAS-X combines fine-mapped Posterior Inclusion Probabilities (PIP) and allelic fold changes (aFC) from pancreas, skeletal muscle, subcutaneous adipose, visceral adipose, and whole blood, then applies a prioritization threshold. It also uses Leave-One-Tissue-Out sensitivity and compares against non-metabolic GTEx Brain Cortex controls.
- The result: Multi-tissue prioritization highlighted candidates including JAZF1, FTO, GRB14, and CDKN2B, with pathway enrichment linked to insulin resistance, adipocytokine signaling, and lipolysis regulation. The framework also incorporates phenome-wide associations and therapeutic tractability assessments to support T2D effector gene selection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.